Uncertain Future For Otelixizumab In Type 1 Diabetes After Phase III Failure
This article was originally published in Pharmaceutical Approvals Monthly
GlaxoSmithKline and Tolerx announced March 11 that their humanized anti-CD3 monoclonal antibody, otelixizumab failed to meet the primary endpoint in the Phase III DEFEND-1 trial for type 1 diabetes, and they were halting recruitment and dosing in another Phase III trial, DEFEND-2, while they review the DEFEND-1 results.
You may also be interested in...
GlaxoSmithKline plans to divest non-core OTC brands this year as CEO describes 2010 as a challenging year.
Tolerx plans to file BLA for humanized anti-CD3 monoclonal antibody in type 1 diabetes in late 2010, CEO tells “The Pink Sheet” DAILY.
Anti-CD3 monoclonal antibody is now in a pivotal Phase II/III clinical trial for treating underlying disease in type 1 diabetes, Lilly tells “The Pink Sheet” DAILY.